- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02810275
Folinic Acid: Supplementation and Therapy (FAST)
Effect of Folic Acid on Homocysteine Levels and Flow-mediated Dilation in HIV and HIV-HCV Coinfected Patients: a Randomized Controlled Trial
Patients infected by HIV or HIV-HCV coinfected have higher survival due to the use of HAART, but survival is accompanied by increased morbidity and associated cardiovascular disease (CVD). Endothelial dysfunction is an early marker of atherogenesis, acting as an intermediate in the causal pathway of CVD. Folinic acid (FA) has been shown to reduce CVD outcomes, especially among individuals with hyperhomocisteinemia.
To date, few studies provided consistent information about efficacy of pharmacological interventions that minimize damage to the vascular endothelium in patients infected by HIV or HIV-HCV coinfected. The main hypothesis of this study is that FA supplementation protects the vascular endothelium, and consequently might prevent subclinical atherosclerosis. Thus, the first step is to determine the efficacy of supplementation with FA, and to compare the effect between HIV and HIV-HCV coinfected.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design: This was a randomized placebo-controlled trial, with blinding of health care team, participants, and investigators, in which the participants were randomly assigned in a 1:1 ratio to receive FA or placebo for four weeks.
Participants: Patients receiving care for HIV, at the outpatient clinic of the Hospital Universitario de Santa Maria, in southern Brazil, from October 2012 to September 2013, were recruited. Eligible participants: HIV infected or HIV-HCV coinfected patients, 18-50 years, men and women, receiving HAART, had undetectable viral load for more than six months. Patients were excluded: patients with diabetes mellitus, previous acute myocardial infarction, myocardial revascularization, or stroke, creatinine >1.5 mg/dL, clinical diagnosis or ultrasound, endoscopic, or laboratory evidence of liver cirrhosis, on treatment with statins, fibrates, hormone replacement therapy, sulfonamides, vitamin supplements, or FA in the last 30 days, and pregnant women.
Intervention Patients assigned to the intervention group received FA 5 mg, per oral, once a day, in the morning, during four weeks. Patients assigned to the placebo group received the same prescription. The trial provided FA and placebo in tablet form, identical in color, smell, taste, shape, and size. Both FA and placebo were prepared in a single batch, in an independent laboratory, by a pharmacist with no involvement in the trial. They were pre-packed in bottles containing 30 tablets each, individually labeled with an alphanumeric code and stored.
Outcomes The primary endpoint were changes in homocysteine, vitamin B12 levels, and brachial artery FMD during reactive hyperemia, as measured by Doppler ultrasound, from randomization to the end of follow-up. FMD was characterized by the variation in mean arterial flow measured as the peak change in vessel diameters relative to the baseline.
Sample size Sample size was calculated based on the results of a previous RCT,(14) which used plethysmography to measure FMD. To detect a difference of at least 6% between intervention and placebo groups, with standard deviations ranging from 5% to 7%, we calculated that a sample size of at least 17 patients per group, with randomization stratified by HCV coinfection status, was required to achieve 80% power and a 95% confidence interval.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- HIV infected patients
- HIV-HCV coinfected patients
- 18-50 years
- men and women
- receiving HAART
- with undetectable viral load for more than six months.
Exclusion Criteria:
- Patients with diabetes mellitus,
- previous CVD: acute myocardial infarction, myocardial revascularization, or stroke,
- creatinine >1.5 mg/dL,
- clinical diagnosis or ultrasound, endoscopic, or laboratory evidence of liver cirrhosis,
- on treatment with: statins, fibrates, hormone replacement therapy, sulfonamides, vitamin supplements, or FA in the last 30 days,
- pregnant women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Folinic Acid
Folinic acid group received 5 mg daily during four weeks
|
Folinic acid 5 mg, taking in the morning, daily, during four weeks
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Placebo group received a tablet daily during four weeks
|
Placebo capsule received 1 tablet, taking in the morning, during four weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Flow mediated dilatation
Time Frame: Four weeks
|
The response was defined by the variation in the flow mediated dilatation between intervention and placebo groups.
|
Four weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum homocysteine
Time Frame: Four weeks
|
Variation in the serum homocysteine between intervention and placebo groups.
|
Four weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood pressure
Time Frame: Four weeks
|
The response was defined by variation in blood pressure between intervention and placebo groups.
|
Four weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Sandra C Fuchs, PhD, MD, Hospital de Clinicas de Porto Alegre
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAAE: 00533612.8.0000.5346
- GPPG-140240 (OTHER_GRANT: Hospital de Clinicas de Porto Alegre - FIPE)
- RBR-9366qc (REGISTRY: Brazilian Clinical Trials Registry (ReBEC))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infection
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Rockefeller UniversityCompletedHIV Infection | Healthy Volunteers | HIV-1 InfectionUnited States
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
AIDS Healthcare FoundationUniversity of California, Los AngelesCompleted
-
Merck Sharp & Dohme LLCCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal AntibodyUnited States
Clinical Trials on Folinic Acid
-
University of ArkansasArkansas Children's Hospital Research InstituteTerminatedAutism Spectrum Disorder | Autistic Disorder | Autism | Pervasive Development Disorders | Asperger's SyndromeUnited States
-
Central Hospital, Nancy, FranceUnknown
-
The Nordic Colorectal Cancer Biomodulation GroupCompletedMetastatic Colorectal CancerNorway
-
Hadassah Medical OrganizationUnknown
-
Nishtar Medical UniversityCompletedAutism Spectrum DisorderPakistan
-
Institut Jerome LejeuneFondation Jérôme LejeuneCompleted
-
Hospital de Clinicas de Porto AlegreCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.Completed
-
Amphia HospitalAlbert Schweitzer HospitalRecruitingNSCLC | Thymoma | MesotheliomaNetherlands
-
Hoffmann-La RocheCompletedColorectal CancerUnited Kingdom
-
The Christie NHS Foundation TrustCancer Research UKCompletedCholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer | Ampullary CancerUnited Kingdom